These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 10821973)

  • 21. Short report: immune response and occurrence of dengue infection in thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine.
    Chanthavanich P; Luxemburger C; Sirivichayakul C; Lapphra K; Pengsaa K; Yoksan S; Sabchareon A; Lang J
    Am J Trop Med Hyg; 2006 Jul; 75(1):26-8. PubMed ID: 16837703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of a tetravalent dengue vaccine in children in Latin America.
    Villar L; Dayan GH; Arredondo-García JL; Rivera DM; Cunha R; Deseda C; Reynales H; Costa MS; Morales-Ramírez JO; Carrasquilla G; Rey LC; Dietze R; Luz K; Rivas E; Miranda Montoya MC; Cortés Supelano M; Zambrano B; Langevin E; Boaz M; Tornieporth N; Saville M; Noriega F;
    N Engl J Med; 2015 Jan; 372(2):113-23. PubMed ID: 25365753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.
    Sun W; Nisalak A; Gettayacamin M; Eckels KH; Putnak JR; Vaughn DW; Innis BL; Thomas SJ; Endy TP
    J Infect Dis; 2006 Jun; 193(12):1658-65. PubMed ID: 16703509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.
    Sirivichayakul C; Barranco-Santana EA; Esquilin-Rivera I; Oh HM; Raanan M; Sariol CA; Shek LP; Simasathien S; Smith MK; Velez ID; Wallace D; Gordon GS; Stinchcomb DT
    J Infect Dis; 2016 May; 213(10):1562-72. PubMed ID: 26704612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of Toxorhynchites splendens for identification and quantitation of serotypes contained in the tetravalent live attenuated dengue vaccine.
    Jirakanjanakit N; Khin MM; Yoksan S; Bhamarapravati N
    Vaccine; 1999 Feb; 17(6):597-601. PubMed ID: 10075167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity.
    McArthur JH; Durbin AP; Marron JA; Wanionek KA; Thumar B; Pierro DJ; Schmidt AC; Blaney JE; Murphy BR; Whitehead SS
    Am J Trop Med Hyg; 2008 Nov; 79(5):678-84. PubMed ID: 18981503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human CD4
    Angelo MA; Grifoni A; O'Rourke PH; Sidney J; Paul S; Peters B; de Silva AD; Phillips E; Mallal S; Diehl SA; Kirkpatrick BD; Whitehead SS; Durbin AP; Sette A; Weiskopf D
    J Virol; 2017 Mar; 91(5):. PubMed ID: 27974563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command.
    Innis BL; Eckels KH
    Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):1-4. PubMed ID: 14756126
    [No Abstract]   [Full Text] [Related]  

  • 29. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.
    Pletnev AG; Bray M; Hanley KA; Speicher J; Elkins R
    J Virol; 2001 Sep; 75(17):8259-67. PubMed ID: 11483771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
    Guy B; Barrere B; Malinowski C; Saville M; Teyssou R; Lang J
    Vaccine; 2011 Sep; 29(42):7229-41. PubMed ID: 21745521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.
    Durbin AP; McArthur JH; Marron JA; Blaney JE; Thumar B; Wanionek K; Murphy BR; Whitehead SS
    Hum Vaccin; 2006; 2(6):255-60. PubMed ID: 17106267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers.
    Durbin AP; Whitehead SS; McArthur J; Perreault JR; Blaney JE; Thumar B; Murphy BR; Karron RA
    J Infect Dis; 2005 Mar; 191(5):710-8. PubMed ID: 15688284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate.
    Anderson KB; Gibbons RV; Edelman R; Eckels KH; Putnak RJ; Innis BL; Sun W
    J Infect Dis; 2011 Aug; 204(3):442-50. PubMed ID: 21742844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dengue type 4 live-attenuated vaccine viruses passaged in vero cells affect genetic stability and dengue-induced hemorrhaging in mice.
    Lee HC; Yen YT; Chen WY; Wu-Hsieh BA; Wu SC
    PLoS One; 2011; 6(10):e25800. PubMed ID: 22053180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of a live attenuated tetravalent candidate dengue vaccine in naïve and previously infected cynomolgus macaques.
    Koraka P; Benton S; van Amerongen G; Stittelaar KJ; Osterhaus AD
    Vaccine; 2007 Jul; 25(29):5409-16. PubMed ID: 17560694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy.
    Simmons M; Burgess T; Lynch J; Putnak R
    Virology; 2010 Jan; 396(2):280-8. PubMed ID: 19913867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii.
    Halstead SB; Marchette NJ
    Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):5-11. PubMed ID: 14740949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers.
    Bhamarapravati N; Yoksan S; Chayaniyayothin T; Angsubphakorn S; Bunyaratvej A
    Bull World Health Organ; 1987; 65(2):189-95. PubMed ID: 3496985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
    Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.